Business

Biotech By Adam Feuerstein

Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis

Biotech By Matthew Herper

Digital event: Combating Covid-19

Business By Andrew Joseph, Adam Feuerstein, Damian Garde and Matthew Herper

Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know

Biotech By Adam Feuerstein

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

Business By Jonathan Saltzman — Boston Globe

Boston Scientific cutting hours and pay as revenue drops

Biotech By Adam Feuerstein

The biotech scorecard for the second quarter: 18 stock-moving events to watch

Biotech By Adam Feuerstein

Amarin loses legal fight over heart drug patent; shares sink

Health By Elizabeth Cooney

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

Biotech By Adam Feuerstein and Matthew Herper

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Biotech By Adam Feuerstein

Drug makers grounding salespeople as coronavirus impact on business spreads

Biotech By Damian Garde and Adam Feuerstein

How one company made $208 million on an untested coronavirus vaccine

Business By Scott Kirsner — Boston Globe

The Engine at MIT is revving up the potential of ‘tough tech’

Biotech By Jonathan Saltzman — Boston Globe

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

Biotech By Matthew Herper

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

Biotech By Adam Feuerstein

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

Biotech By Adam Feuerstein

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

Biotech By Jonathan Saltzman — Boston Globe

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

Biotech By Adam Feuerstein

Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk

Opinions+ By Jonathan P. Gertler

Why medtech is a different beast than biotech in the life sciences pack

Biotech By Adam Feuerstein

With new combination drug data, Exelixis takes another shot at prostate cancer treatment

Adam's Take By Adam Feuerstein

Investor impatience with Gilead reclamation project sparks acquisition chatter

Biotech By Jonathan Saltzman — Boston Globe

Beam Therapeutics raises $180 million in IPO

Health Tech By Erin Brodwin

Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so

Biotech By Adam Feuerstein

Biogen wins patent challenge to key multiple sclerosis drug

Exclusive By Erin Brodwin

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

Biotech By Adam Feuerstein

FDA approves the first treatment for peanut allergy, but commercial success is hardly assured

Biotech By Adam Feuerstein

European regulators could take a harder line on the review of an Agios blood cancer drug

Adam's Take By Adam Feuerstein

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

Biotech By Jonathan Saltzman — Boston Globe

Spring Bank scraps hepatitis R&D after patient dies in trial